Phu Tran, MD
Hematology & Oncology · Port St Lucie, FLNPI 1891089587
Payments from drug & device makers
Across 830 payments — averaging $79.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$34K
- AstraZeneca$12K
- Karyopharm Therapeutics Inc.$3K
- Novartis$2K
- Boehringer Ingelheim$2K
- Pfizer$2K
- plus $11K from 50 others
What the payments were for
- Consulting fees$11,03834%
- Speaking & faculty fees$2801%
- Travel & lodging$4,76815%
- Food & beverage$13,88943%
- Education$5822%
- Other$1,6315%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$9,515
- XPOVIO$3,193
- CALQUENCE$1,050
- Truqap$525
- OSTEOCOOL RF ABLATION SYSTEM$136
How this compares
$65,830 in reported general payments places this provider in the 60th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 83 | $1,135,028 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 52 | $709,752 |
| RevlimidLenalidomide | 37 | $673,905 |
| XtandiEnzalutamide | 38 | $539,277 |
| CalquenceAcalabrutinib Maleate | 24 | $359,412 |
| BrukinsaZanubrutinib | 23 | $346,998 |
| ScemblixAsciminib Hydrochloride | 14 | $298,679 |
| ImbruvicaIbrutinib | 19 | $287,128 |
| LynparzaOlaparib | 18 | $187,132 |
| JakafiRuxolitinib Phosphate | 12 | $184,114 |
| VenclextaVenetoclax | 16 | $164,194 |
| NinlaroIxazomib Citrate | 12 | $162,534 |
| Lupron DepotLeuprolide Acetate | 22 | $139,874 |
| Somatuline DepotLanreotide Acetate | 14 | $129,061 |
| ZirabevBevacizumab-Bvzr | 26 | $105,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $494 | $673,90537 claims |
| AstraZenecaCalquence, Lynparza | $12,429 | $546,54442 claims |
| Astellas Pharma US IncXtandi | $278 | $539,27738 claims |
| Beigene USA, Inc.Brukinsa | $238 | $346,99823 claims |
| AbbVieVenclexta, Lupron Depot, Creon | $342 | $314,35649 claims |
| NovartisScemblix | $2,151 | $298,67914 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $49 | $287,12819 claims |
| PfizerZirabev, Eliquis, Trazimera, Nivestym | $1,515 | $267,036182 claims |
| Incyte CorporationJakafi | $748 | $184,11412 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $384 | $162,53412 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $181 | $129,06114 claims |
| Johnson & JohnsonXarelto | $783 | $51,88056 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Port St Lucie
- Seth RosenPort St Lucie$5.5M
- Nicholas IannottiPort St Lucie$3.2M
- Carl LandgrenMiami$47.8M
- Julio ChavezTampa$16.4M
- Steven AttiaJacksonville$13.9M
- Santosh NairOrange City$13.5M
- Frederick LockeTampa$12.8M
- Tarek MekhailOrlando$11.2M
- Carlos AlemanyOrlando$10.9M
- Thomas GeorgeGainesville$10.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.